Form 4 for IDXX Idexx Laboratories
Accepted 2023-12-08 00:00:00 ET · period of report 2023-12-07 · accession 0000874716-23-000145 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-12-08 | 2023-12-07 | IDXX | POLEWACZYK JAMES F | EVP | M - OptEx | $253.92 | +11.6K | 21.7K | +116% | +$2.95M |
| DM | 2023-12-08 | 2023-12-07 | IDXX | POLEWACZYK JAMES F | EVP | S - Sale+OE | $521.79 | -11.6K | 15.2K | -43% | -$6.07M |
| DM | 2023-12-08 | 2023-12-07 | IDXX | POLEWACZYK JAMES F | EVP | M - OptEx | $0.00 | -11.6K | 2,226 | -84% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-07 | M | A | 4,956 | $206.94 | 15,005.99 | D | — | — | (F1) Includes 12 shares purchased under the Issuer's Employee Stock Purchase Plan on September 29, 2023. |
| 2 | Common | Common Stock | 2023-12-07 | M | A | 6,680 | $288.78 | 21,685.99 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-07 | S | D | 3,116 | $520.19 | 18,569.99 | D | — | — | (F2) Represents the weighted average price of the shares sold ranging from a low of $519.73 to a high of $520.73 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 4 | Common | Common Stock | 2023-12-07 | S | D | 1,202 | $522.31 | 13,989.99 | D | — | — | (F4) Represents the weighted average price of the shares sold ranging from a low of $521.99 to a high of $522.935 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 5 | Common | Common Stock | 2023-12-07 | S | D | 3,940 | $523.56 | 10,049.99 | D | — | — | (F5) Represents the weighted average price of the shares sold ranging from a low of $523.05 to a high of $523.885 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 6 | Common | Common Stock | 2023-12-07 | S | D | 3,378 | $521.00 | 15,191.99 | D | — | — | (F3) Represents the weighted average price of the shares sold ranging from a low of $520.74 to a high of $521.235 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| 7 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2023-12-07 | M | D | 4,956 | $0.00 | 755 | D | $206.94 · — to 2029-02-13 | 4,956 Common Stock | (F6) Grant of option to buy 5,711 shares of Issuer common stock that vest in five annual installments beginning February 14, 2020. |
| 8 | Derivative | Non-Qualified Stock Option (right-to-buy) | 2023-12-07 | M | D | 6,680 | $0.00 | 2,226 | D | $288.78 · — to 2030-02-13 | 6,680 Common Stock | (F7) Grant of option to buy 8,906 shares of Issuer common stock that vest in four annual installments beginning February 14, 2021. |